There is provided a novel LXRβ agonist useful as a preventative and/or therapeutic agent for arteriosclerosis； arteriosclerosis such as those resulting from diabetes； hyperlipidemia； hypercholesterolemia； lipid-related diseases； inflammatory diseases caused by inflammatory cytokines, skin diseases such as allergic skin diseases, diabetes or Alzheimer's disease. The agonist is a carbinol derivative represented by the following general formula (1) or salt thereof, or their solvate.
